Mapi - Pharma (Mapi - Pharma) EPS (Basic) : $-0.87 (TTM As of Jun. 2015)

View and export this data going back to . Start your Free Trial

What is Mapi - Pharma EPS (Basic)?

Mapi - Pharma's basic earnings per share (Basic EPS) for the six months ended in Jun. 2015 was $-0.25. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2015 was $-0.87.

Mapi - Pharma's EPS (Diluted) for the six months ended in Jun. 2015 was $-0.25. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2015 was $-0.87.

Mapi - Pharma's EPS without NRI for the six months ended in Jun. 2015 was $-0.25. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2015 was -0.87.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Mapi - Pharma EPS (Basic) Historical Data

The historical data trend for Mapi - Pharma's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mapi - Pharma EPS (Basic) Chart

Mapi - Pharma Annual Data

Trend

Dec12

Dec13

Dec14

EPS (Basic)

-0.91

Mapi - Pharma Semi-Annual Data
	Dec12	Dec13	Jun14	Dec14	Jun15
EPS (Basic)	-	-	-0.30	-0.62	-0.25

Mapi - Pharma EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Mapi - Pharma's Basic EPS for the fiscal year that ended in Dec. 2014 is calculated as

Basic EPS (A: Dec. 2014 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-6.444	-	0)	/	7.057
	=	-0.91

Mapi - Pharma's Basic EPS for the quarter that ended in Jun. 2015 is calculated as

Basic EPS (Q: Jun. 2015 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-2.281	-	0)	/	7.057
	=	-0.32

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2015 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.87

Mapi - Pharma (NAS:MAPI) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Mapi - Pharma EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Mapi - Pharma's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Mapi - Pharma (Mapi - Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mapi - Pharma Ltd (NAS:MAPI) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.mapi-pharma.com

Mapi - Pharma Ltd was incorporated under the laws of the State of Israel on January 29, 2008. It is a development stage pharmaceutical company, engaged in the development of high-barrier to entry and high-added value generic drugs that include complex active pharmaceutical ingredients or APIs, formulations and life cycle management or LCM products that target large markets. The Company is developing two LCM products for the treatment of multiple sclerosis and neuropathic pain. It is also developing a portfolio of approximately 13 complex APIs. Its LCM portfolio focuses on market product, consisting of Glatiramer Acetate Depot, a once-monthly injection for the treatment of MS, Pregabalin ER, extended release capsules for the treatment of neuropathic pain and epilepsy, and Risperidone LAI, a depot formulation of Risperdal Consta, expected to be developed under the abbreviated new drug application ANDA or 505(b)(2) shortened regulatory pathway. Its competitors in the generic pharmaceutical products and LCM markets includes Teva Pharmaceutical Industries Ltd.; Impax Laboratories, Inc.; Alkermes Plc.; Momenta Pharmaceuticals, Inc.; and Andrx Corporation; a private U.S. company. The Company's current patent portfolio contains approximately 20 patent applications for complex APIs, formulations, polymorphs, and routes of synthesis. Its operations are subject to many governmental regulations.